Comparison criteria

This page is a knowledge crystal of subtype variable. The page identifier is Op_en6356
Moderator:Nobody (see all) Click here to sign up.
Upload data {{#opasnet_base_link:Op_en6356}}

Progression class

In Opasnet many pages being worked on and are in different classes of progression. Thus the information on those pages should be regarded with consideration. The progression class of this page has been assessed: This page is a draft The relevat content and structure of the page is already present, but there still is a lot of missing content.

This page needs a curator. Learn more about curating Opasnet pages.

Question

Which comparison criteria should be used in the tendering process for the selection of a pneumococcal conjugate vaccine to be included in the national vaccination programme for children in Finland? The tendering process will be initiated during the autumn of 2014.

• Possible comparison criteria include price, benefits, safety and technical properties.
  • Price refers to the bargaining price of the vaccine.
  • Benefits refer to the decrease in disease burden caused by large scale use of the vaccine. As a result health care costs decrease and the quality of life attributed to improved health increases.
  • Safety
  • Technical properties
• The benefits of the pneumococcal conjugate vaccine are quantified by the decrease of disease caused by pneumococcus and Haemophilus influenzae -bacteria.
• The benefits are assessed in the entire Finnish population.

Answer

The tentative proposal is that the comparison is based on price and assessed benefits. Benefits are quantified as the expected decrease in invasive pneumococcal disease incidence due to vaccination. This tentative proposal is the basis for the conversation beginning in the summer of 2014.

Rationale

According to the public procurement law, comparison criteria related to differences in the products can be applied if (1) the differences are clearly demonstrated and (2) the differences can be quantified in terms of increased or decreased benefits. In particular, technical differences typically fall outside of this realm. So far no credible differences in safety among the currently licensed pneumococcal conjugate vaccines have been demonstrated.